Drug Trial Radar · NCT03747575
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Feb 6, 2019
Primary completion
Mar 11, 2020
Study completion May 5, 2020
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
Conditions
- Atopic Dermatitis
Interventions
MSTT1041ADrug
Participants will receive subcutaneous (SC) MSTT1041A
PlaceboDrug
Participants will receive SC placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change of Total Eczema Area and Severity Index (EASI) ScoreTime frame: Baseline, Week 16
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
Alabama Allergy & Asthma
Birmingham, Alabama
California Allergy and Asthma Medical Group - CRN
Los Angeles, California
Jonathan Corren MD, Inc.
Los Angeles, California
Asthma & Allergy; Associates, P.C.
Colorado Springs, Colorado
South Coast Research Center, Inc.
Miami, Florida
Harmony Clinical Research, Inc
North Miami Beach, Florida
GCP Global Clinical Professionals
St. Petersburg, Florida
Forward Clinical Trials
Tampa, Florida
Florida Pulmonary Research Institute, LLC
Winter Park, Florida
Midwest Sinus Allergy and Asthma - CRN
Normal, Illinois
Dermatology Specialists Research, LLC
Louisville, Kentucky
Clinical Research Consortium Nevada
Las Vegas, Nevada
Skin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS
Hackensack, New Jersey
Vital Prospects Clinical Research Institute PC - CRN
Tulsa, Oklahoma
Center for Clinical Studies
Houston, Texas
Universitatsklinikum Munster
Münster, Germany
Centrum Medyczne ALL-MED
Krakow, Poland
SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
Lodz, Poland
Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina; Klinika Dermatologii
Rzeszów, Poland
Laser Clinic
Szczecin, Poland
Wro Medica
Wroc?aw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.